Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. OTC Markets
  5. Endo International plc
  6. Financials
    ENDPQ   IE00BJ3V9050

ENDO INTERNATIONAL PLC

(ENDPQ)
  Report
Delayed OTC Markets  -  03:59:49 2023-02-01 pm EST
0.1017 USD   +7.17%
01/24Endo International Plc : Other Events (form 8-K)
AQ
01/03Endo International Plc : Other Events (form 8-K)
AQ
2022Novartis Strikes $245 Million Settlement to End Antitrust Lawsuits Over Hypertension Drug Generics
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusFunds 
Valuation
Fiscal Period: December 2016 2017 2018 2019 2020 2021
Capitalization1 3 6711 7311 6381 0641 653879
Enterprise Value (EV)1 11 4729 0568 7868 0998 8367 691
P/E ratio -1,10x-0,85x-1,59x-2,50x9,11x-1,43x
Yield ------
Capitalization / Revenue 0,92x0,50x0,56x0,36x0,57x0,29x
EV / Revenue 2,86x2,61x2,98x2,78x3,04x2,57x
EV / EBITDA 19,2x12,1x13,8x12,1x11,2x8,72x
Enterprise Value (EV) / FCF 8,39x6,64x17,8x40,0x27,5x10,1x
FCF Yield 11,9%15,0%5,61%2,50%3,64%9,92%
Price to Book 1,36x3,57x-3,29x-1,23x-2,55x-0,71x
Nbr of stocks (in thousands) 222 877223 313224 345226 776230 292233 671
Reference price (USD) 16,57,757,304,697,183,76
Announcement Date 03/01/201702/27/201802/28/201902/26/202002/26/202103/01/2022
1 USD in Million
Income Statement Evolution (Annual data)
Fiscal Period: December 2016 2017 2018 2019 2020 2021
Net sales1 4 0103 4692 9472 9142 9032 993
EBITDA1 596745638669791882
Operating profit (EBIT)1 455630544588692793
Operating Margin 11,3%18,2%18,5%20,2%23,8%26,5%
Pre-Tax Profit (EBT)1 -3 924-1 483-939-345-26,5-547
Net income1 -3 347-2 035-1 031-423184-613
Net margin -83,5%-58,7%-35,0%-14,5%6,34%-20,5%
EPS2 -15,0-9,12-4,61-1,870,79-2,63
Free Cash Flow1 1 3671 363493202321763
FCF margin 34,1%39,3%16,7%6,95%11,1%25,5%
FCF Conversion 229%183%77,2%30,3%40,6%86,5%
Dividend per Share ------
Announcement Date 03/01/201702/27/201802/28/201902/26/202002/26/202103/01/2022
1 USD in Million
2 USD
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q1 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2
Net sales1 718714772789652569
EBITDA1 365343387387311160
Operating profit (EBIT)1 338322365367294145
Operating Margin 47,1%45,1%47,2%46,5%45,0%25,5%
Pre-Tax Profit (EBT) 47,8-----
Net income1 41,5-15,5-77,2-562-72,0-1 885
Net margin 5,78%-2,17%-10,0%-71,2%-11,0%-331%
EPS 0,17-0,04-0,33---
Dividend per Share ------
Announcement Date 05/06/202108/05/202111/04/202102/28/202205/05/202208/09/2022
1 USD in Million
Previous periodNext period
Balance Sheet Analysis
Fiscal Period: December 2016 2017 2018 2019 2020 2021
Net Debt1 7 8017 3257 1497 0367 1826 812
Net Cash position1 ------
Leverage (Debt / EBITDA) 13,1x9,83x11,2x10,5x9,08x7,72x
Free Cash Flow1 1 3671 363493202321763
ROE (Net Profit / Equities) -74,4%-77,4%14 352%52,8%-32,7%60,2%
Shareholders' equity1 4 5012 631-7,19-800-563-1 019
ROA (Net Profit / Asset) 1,69%3,04%3,13%3,76%4,63%5,50%
Assets1 -198 004-66 944-33 006-11 2343 970-11 155
Book Value Per Share2 12,12,17-2,22-3,82-2,81-5,32
Cash Flow per Share2 2,324,425,126,415,276,45
Capex1 13912686,967,772,980,7
Capex / Sales 3,46%3,62%2,95%2,32%2,51%2,69%
Announcement Date 03/01/201702/27/201802/28/201902/26/202002/26/202103/01/2022
1 USD in Million
2 USD
Analysis
Teva, Allergan reach $161.5 mln opioid settlement with West Virginia
Key data
Capitalization (USD) 23 919 814
Net sales (USD) 2 993 206 000
Number of employees 3 103
Sales / Employee (USD) 964 617
Free-Float 99,2%
Free-Float capitalization (USD) 23 732 806
Avg. Exchange 20 sessions (USD) 91 453
Average Daily Capital Traded 0,38%
EPS & Dividend
Change in Enterprise Value/EBITDA